vs

Side-by-side financial comparison of P10, Inc. (PX) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $81.0M, roughly 1.8× P10, Inc.). P10, Inc. runs the higher net margin — 11.7% vs -5.3%, a 17.0% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $2.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 10.7%).

P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

PX vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
1.8× larger
TOI
$142.0M
$81.0M
PX
Growing faster (revenue YoY)
TOI
TOI
+46.2% gap
TOI
41.6%
-4.7%
PX
Higher net margin
PX
PX
17.0% more per $
PX
11.7%
-5.3%
TOI
More free cash flow
PX
PX
$15.9M more FCF
PX
$18.1M
$2.2M
TOI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
10.7%
PX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PX
PX
TOI
TOI
Revenue
$81.0M
$142.0M
Net Profit
$9.5M
$-7.5M
Gross Margin
Operating Margin
31.9%
-4.9%
Net Margin
11.7%
-5.3%
Revenue YoY
-4.7%
41.6%
Net Profit YoY
79.0%
43.0%
EPS (diluted)
$0.08
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PX
PX
TOI
TOI
Q4 25
$81.0M
$142.0M
Q3 25
$75.9M
$136.6M
Q2 25
$72.7M
$119.8M
Q1 25
$67.7M
$104.4M
Q4 24
$85.0M
$100.3M
Q3 24
$74.2M
$99.9M
Q2 24
$71.1M
$98.6M
Q1 24
$66.1M
$94.7M
Net Profit
PX
PX
TOI
TOI
Q4 25
$9.5M
$-7.5M
Q3 25
$2.1M
$-16.5M
Q2 25
$3.4M
$-17.0M
Q1 25
$4.5M
$-19.6M
Q4 24
$5.3M
$-13.2M
Q3 24
$1.4M
$-16.1M
Q2 24
$7.0M
$-15.5M
Q1 24
$5.0M
$-19.9M
Operating Margin
PX
PX
TOI
TOI
Q4 25
31.9%
-4.9%
Q3 25
14.1%
-5.9%
Q2 25
24.4%
-9.4%
Q1 25
16.6%
-9.5%
Q4 24
26.9%
-11.9%
Q3 24
11.9%
-13.9%
Q2 24
23.7%
-16.6%
Q1 24
18.3%
-19.0%
Net Margin
PX
PX
TOI
TOI
Q4 25
11.7%
-5.3%
Q3 25
2.8%
-12.1%
Q2 25
4.7%
-14.2%
Q1 25
6.7%
-18.8%
Q4 24
6.2%
-13.1%
Q3 24
1.9%
-16.1%
Q2 24
9.8%
-15.7%
Q1 24
7.6%
-21.0%
EPS (diluted)
PX
PX
TOI
TOI
Q4 25
$0.08
$-0.04
Q3 25
$0.02
$-0.14
Q2 25
$0.03
$-0.15
Q1 25
$0.04
$-0.21
Q4 24
$0.05
$-0.14
Q3 24
$0.01
$-0.18
Q2 24
$0.06
$-0.17
Q1 24
$0.04
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PX
PX
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$28.2M
Total DebtLower is stronger
$373.2M
Stockholders' EquityBook value
$403.5M
$-15.7M
Total Assets
$928.3M
$164.7M
Debt / EquityLower = less leverage
0.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PX
PX
TOI
TOI
Q4 25
$28.2M
Q3 25
$40.0M
Q2 25
$33.4M
Q1 25
$74.4M
Q4 24
$67.5M
Q3 24
$61.5M
Q2 24
$31.2M
$9.9M
Q1 24
$29.0M
$29.8M
Total Debt
PX
PX
TOI
TOI
Q4 25
$373.2M
Q3 25
$393.4M
Q2 25
$373.0M
Q1 25
$357.2M
Q4 24
$319.8M
Q3 24
$319.4M
Q2 24
$300.6M
Q1 24
$314.0M
Stockholders' Equity
PX
PX
TOI
TOI
Q4 25
$403.5M
$-15.7M
Q3 25
$396.8M
$-12.3M
Q2 25
$388.9M
$-9.0M
Q1 25
$374.3M
$5.1M
Q4 24
$386.9M
$3.6M
Q3 24
$394.1M
$15.5M
Q2 24
$396.9M
$29.2M
Q1 24
$400.1M
$41.3M
Total Assets
PX
PX
TOI
TOI
Q4 25
$928.3M
$164.7M
Q3 25
$936.0M
$163.6M
Q2 25
$932.2M
$159.8M
Q1 25
$877.4M
$164.0M
Q4 24
$869.3M
$172.7M
Q3 24
$857.0M
$179.2M
Q2 24
$823.2M
$179.6M
Q1 24
$832.8M
$204.5M
Debt / Equity
PX
PX
TOI
TOI
Q4 25
0.93×
Q3 25
0.99×
Q2 25
0.96×
Q1 25
0.95×
Q4 24
0.83×
Q3 24
0.81×
Q2 24
0.76×
Q1 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PX
PX
TOI
TOI
Operating Cash FlowLast quarter
$23.0M
$3.2M
Free Cash FlowOCF − Capex
$18.1M
$2.2M
FCF MarginFCF / Revenue
22.3%
1.5%
Capex IntensityCapex / Revenue
6.0%
0.7%
Cash ConversionOCF / Net Profit
2.43×
TTM Free Cash FlowTrailing 4 quarters
$14.1M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PX
PX
TOI
TOI
Q4 25
$23.0M
$3.2M
Q3 25
$-8.6M
$-12.6M
Q2 25
$13.4M
$-10.2M
Q1 25
$-4.7M
$-5.0M
Q4 24
$101.0M
$4.2M
Q3 24
$27.5M
$819.0K
Q2 24
$34.8M
$-15.7M
Q1 24
$11.0M
$-15.9M
Free Cash Flow
PX
PX
TOI
TOI
Q4 25
$18.1M
$2.2M
Q3 25
$-9.5M
$-13.2M
Q2 25
$11.6M
$-11.4M
Q1 25
$-6.0M
$-5.3M
Q4 24
$96.6M
$2.4M
Q3 24
$25.2M
$417.0K
Q2 24
$33.9M
$-17.5M
Q1 24
$10.7M
$-16.5M
FCF Margin
PX
PX
TOI
TOI
Q4 25
22.3%
1.5%
Q3 25
-12.6%
-9.7%
Q2 25
15.9%
-9.5%
Q1 25
-8.9%
-5.1%
Q4 24
113.6%
2.4%
Q3 24
34.0%
0.4%
Q2 24
47.7%
-17.7%
Q1 24
16.2%
-17.4%
Capex Intensity
PX
PX
TOI
TOI
Q4 25
6.0%
0.7%
Q3 25
1.2%
0.4%
Q2 25
2.5%
1.0%
Q1 25
1.9%
0.3%
Q4 24
5.2%
1.8%
Q3 24
3.0%
0.4%
Q2 24
1.3%
1.9%
Q1 24
0.4%
0.6%
Cash Conversion
PX
PX
TOI
TOI
Q4 25
2.43×
Q3 25
-4.01×
Q2 25
3.96×
Q1 25
-1.05×
Q4 24
19.12×
Q3 24
19.54×
Q2 24
4.98×
Q1 24
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PX
PX

Management Fees$78.1M96%
Advisory Fees$1.8M2%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons